Some seniors pay more for generic drugs than brands
Add Axios as your preferred source to
see more of our stories on Google.
Seniors who use generic specialty drugs may end up spending more out-of-pocket than those who use the brand version because of how Medicare's prescription drug benefit is structured, according to a new study in Health Affairs.
The bottom line: "If you need a lot of drugs or some very expensive drugs you would save more money out-of-pocket by using brands instead of generics," tweeted one of the study's authors, Stacie Dusetzina.
Details: The problem is most acute for specialty drugs, which tend to be the most expensive on the market.
- Branded drug companies pay discounts in Medicare's "donut hole," which count toward that senior's overall out-of-pocket spending. Generics don't, so it takes longer for seniors using those drugs to spend enough for the government to start picking up more of their costs.
- While Congress fixed the problem for biosimilars (akin to the generic version of biologics) last year, it left traditional small-molecule drugs unaddressed.
By the numbers: Even where competition among drugs is robust, patients whose prescriptions cost between $22,000 and $80,000 per year would save money if they used brand-name drugs instead of generics, the study found.
- Part D plans may cover either the brand or the generic version of a drug, meaning patients can't switch between them even if they could get a better deal.
What they're saying: "We need to redesign [Part D] to work for people needing high-priced drugs. All of them. And we need to make generics CONSISTENTLY less expensive for patients than brands," Dusetzina tweeted.
- Congress is considering restructuring Part D as part of its effort to lower drug prices.
